AstraZeneca’s breakthrough in lung cancer treatment: Datopotamab deruxtecan achieves promising survival rates
AstraZeneca's datopotamab deruxtecan (Dato-DXd), a cutting-edge TROP2-directed antibody-drug conjugate, has demonstrated encouraging overall survival results in the TROPION-Lung01 Phase III trial, which focused on patients ... Read More
Datopotamab deruxtecan shows promise in Phase III trial for NSCLC
AstraZeneca and Daiichi Sankyo have announced promising results from the TROPION-Lung01 Phase III trial, highlighting datopotamab deruxtecan's potential as a treatment for advanced nonsquamous non-small ... Read More